

Expert Opinion: Omega-3 Fatty Acids and Bleeding—Cause for Concern?

William S. Harris, PhD

Omega-3 fatty acid ethyl esters have well-known triglyceride-lowering properties and were shown >30 years ago to inhibit platelet function. With the recent US Food and Drug Administration (FDA) approval of these agents for treating severe triglyceride elevations, concerns about excess bleeding naturally arise. However, an objective assessment of the evidence for clinically significant bleeding reveals that such concerns are unfounded. As such, the benefits of triglyceride lowering with omega-3 fatty acids more than outweigh any theoretical risks for increased bleeding. © 2007 Elsevier Inc. All rights reserved. (Am J Cardiol 2007;99[suppl]:44C–46C)

As the health benefits of omega-3 fatty acids become clearer, interest in defining the potential adverse effects of these nutrients naturally increases. In the review by Bays¹ in this supplement, the possibility of increased risk for bleeding with omega-3 fatty acids is addressed. Bays clearly describes the role of omega-3 fatty acids in eicosanoid metabolism, which forms the biochemical basis for the concern for increased bleeding with omega-3 fatty acids. He concludes that although there is little evidence for increased risk for clinically significant bleeding with omega-3 fatty acid supplementation, clinicians should be mindful of this as a theoretical possibility. This commentary provides a more detailed discussion of the evidence supporting this conclusion.

The relevant clinical question is the following: What is the evidence that taking long-chain omega-3 fatty acids in doses of 1–4 g/day causes clinically significant bleeding? To answer that question, studies were examined in which these doses (and typically even greater doses) were provided to patients who underwent major vascular surgery (coronary artery bypass grafting or endarterectomy) or femoral artery puncture for either diagnostic cardiac catheterization or percutaneous transluminal coronary angioplasty.

There have been 2 studies in which patients who underwent coronary artery bypass grafting were given omega-3 fatty acids, 2 trials including carotid endarterectomy, and 15 trials in which omega-3 fatty acids were tested in patients who underwent femoral artery catheterization. These studies are summarized in Table 1,^{2–20} along with the concomitant medications and findings with regard to bleeding com-

plications. In these studies, the risk for clinically significant bleeding was virtually nonexistent.

Several years ago, Knapp²¹ reviewed the published research regarding omega-3 fatty acids and human thrombosis and hemostasis. In addition to noting the lack of significant bleeding with omega-3 fatty acid supplementation in cardiovascular studies to date, he also referred to studies in pregnant women in which supplementation with omega-3 fatty acids 2.7 g/day did not lead to increased blood loss at delivery,²² and he noted that supplemented dialysis patients were not at increased risk for bleeding.^{23,24} There had been 1 report that fish oil (5 g) caused increased risk for nosebleeds in children with hypercholesterolemia,²⁵ but this could not be replicated in a later trial in children on dialysis.²⁶

Thus, the experience has been virtually unanimous: omega-3 fatty acid supplements do not increase the risk for clinically significant bleeding, even in patients also being treated with antiplatelet or antithrombotic medications. Anecdotal reports of an increased bruising tendency have not been tested in a controlled setting, nor has the possible adverse interaction between omega-3 fatty acids and newer antiplatelet drugs (eg, clopidogrel) been examined directly.

Given our present knowledge, I would agree with Bays¹ that we are “confident” that omega-3 fatty acids do not increase risk for adverse bleeding episodes. However, I would consider the evidence to be at the “A” (well designed randomized controlled clinical trials)—instead of “C” (reports to regulatory agencies; multiple case studies; strong trends; prospective cohort studies; metabolic or clinical surrogate studies)—level, given the number of randomized, controlled clinical trials in which these agents were found to be safe, bearing in mind that more studies are still needed to determine the combined effects of glycoprotein IIb/IIIa inhibitors and omega-3 fatty acids. Nevertheless, in considering the risks and benefits of omega-3 fatty acids for cardiovascular risk reduction, the latter continue to outweigh the former.

Sanford School of Medicine of the University of South Dakota, Sioux Falls, South Dakota, USA.

Address for reprints: William S. Harris, PhD, Department of Medicine, Sanford School of Medicine of the University of South Dakota, 1400 West 22nd Street, Sioux Falls, South Dakota 57105.

E-mail address: bill.harris@usd.edu.

Table 1
Summary of reports of the effects of omega-3 fatty acids on bleeding complications

Procedure	EPA + DHA Dose (Product)	Pretreatment (days)	Duration (mo)	Patients (n)	Concomitant Medications	Bleeding Complications
CABG ²	3.4 g (Omacor)*	2	12	610	Aspirin or warfarin	"The bleeding time increased moderately in both groups, and there was no group difference"
CABG ³	4.3 g (unnamed) fish oil [†]	28	To surgery	30	Heparin during CABG	"The patients . . . did not have significantly increased bleeding at or after surgery compared to matched controls"
PTCA ⁴	3.6 g (MaxEPA) [‡]	0	12	108	None	No patient had undesirable bleeding effects, and the combination appears quite safe
PTCA ⁵	3.0 g (MaxEPA) [‡]	1–2	6	120	Aspirin, dipyridimole, CCB, nitrates	Only adverse events reported were: nausea (n = 4) and diarrhea (n = 1)
PTCA ⁶	6.9 g (NIH Fish Oil) [§]	12–14	6	447	Aspirin	"No difference in clinically significant bleeding was noted. . . All bleeding times were within the normal range"
PTCA ⁷	5.4 g (MaxEPA) [‡]	7	6	82	Aspirin and dipyridimole	"We did not observe a significant prolongation of bleeding time"
PTCA ⁸	3.15 g (Ameu)	0	4.5	204	Aspirin	"None of the patients demonstrated or reported on bleeding complications"
PTCA ⁹	4.5 g (Promega) [¶]	0	6	194	Aspirin	No specific mention of bleeding, but stated that "six months of therapy appears safe"
PTCA ¹⁰	5.4 g (MaxEPA) [‡]	6	4.5	814	Aspirin (all); 50% also taking low-molecular-weight heparin	"Bleeding less frequent in fish oil group"
PTCA ¹¹	3 g (MaxEPA) [‡]	1	4	108	Aspirin	"No patient suffered from bleeding complications"
PTCA ¹²	3 g (MaxEPA)	4.3	6	107	Aspirin and CCB	"No patients suffered from bleeding complications during follow up"
PTCA ¹³	4.5 g (MaxEPA) [‡]	21	6	205	Aspirin	"None of the patients reported bleeding . . . attributable to the fish oil supplements"
PTCA ¹⁴	6 g (Super EPA 500 ^H or Promega)	5.4	4.5	242	Aspirin and dipyridimole	4 events in 124 patients in the omega-3 group: at PTCA, 2 at puncture site; on study, 1 gastrointestinal bleed requiring transfusion and 1 heme-positive stool (nonsignificant vs placebo)
PTCA ¹⁵	5.1 g (Omacor)*	14	6	388	Aspirin, nitrates, heparin, and nifedipine, all during procedure	Bleeding not mentioned: "no obvious adverse effects to the capsules were noted"
PTCA ¹⁶	5.1 g before, 2.6 g after (Esapent)*	30	6	257	Aspirin	"Lack of any significant side effect [on] bleeding"
Endarterectomy ¹⁷	1.4 g/day (MaxEPA) [‡]	42	Through surgery	170	Aspirin (100% of patients)	"No bleeding complications were noted during the intervention period or in the immediate period post-surgery" (P. Calder, personal communication)
Endarterectomy ¹⁸	16–21 g/day (MaxEPA) [‡]	Median 30	Through surgery	29	None listed	"There were no clinically significant bleeding complications" (J. Rapp, personal communication)
Coronary angiography ¹⁹	3.3 g for 3 mo; 1.6 g for 21 mo [‡]	None	24	223	Aspirin (91% of patients)	"Minor hematoma, but no other complication, was associated with the second episode of coronary angiography"
Coronary angiography ²⁰	4.8 g (Promega) ^H	None	28	59	Aspirin (95% of patients)	"There were no serious adverse events related to bleeding. This was not an issue for the cardiologists doing the cath" (F. Sacks, personal communication)

CABG = coronary artery bypass grafting; CCB = calcium channel blocker; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; EPA and DHA composition of products used (ee = ethyl ester; tg = triglyceride); Esapent: trade name of Omacor in Italy at that time; MaxEPA (or Ameu): 30% EPA + DHA tg; ratio = 1.5:1.0; NIH Fish Oil: 80% EPA + DHA ee; ratio = 1.5:1.0; NIH fish oil (fish oils test materials-now defunct); Omacor: 84% EPA + DHA ee; EPA/DHA ratio = 1.2:1.0; Promega: 50% EPA + DHA ee; ratio = 2.3:1.0; PTCA = percutaneous transluminal coronary angioplasty; Super EPA 500: 56% EPA + DHA ee; ratio 1:1; Unnamed fish oil; 43% EPA + DHA ee; ratio 2.3:1.0. * Pronova Biocare, Oslo, Norway; [†] PGE Technologies, Marblehead, MA; [‡] Seven Seas Health Care, Hull, United Kingdom; [§] National Institutes of Health, Office of Dietary Supplements; ^{||} Omega-Pharma, Berlin, Germany; [¶] Parke-Davis, Morris Plains, NJ; ^H Pharmcaps Corporation, Elizabeth, NJ.

1. Bays HE. Safety considerations with omega-3 fatty acid therapy. *Am J Cardiol* 2007;99(suppl):35C–43C.
2. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. *Am J Cardiol* 1996;77:31–36.
3. DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzarini G, Maffei S, Cerri M, Salvatore L, Weksler B. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. *Circulation* 1990;82:428–438.
4. Nye ER, Ablett MB, Robertson MC, Ilesley CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. *Aust N Z J Med* 1990;20:549–552.
5. Bellamy CM, Schofield PM, Faragher EB, Ramsdale DR. Can supplementation of diet with omega-3 polyunsaturated fatty acids reduce coronary angioplasty restenosis rate? *Eur Heart J* 1992;13:1626–1631.
6. Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J, Weiner BH, Slack JD, Kellett MA, Raizner AE, et al. Do fish oils prevent restenosis after coronary angioplasty? *Circulation* 1994;90:2248–2257.
7. Dehmer GJ, Popma JJ, van den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. *N Engl J Med* 1988;319:733–740.
8. Franzen D, Schannwell M, Oette K, Hopp HW. A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following PTCA. *Cathet Cardiovasc Diagn* 1993;28:301–310.
9. Milner MR, Gallino RA, Leffingwell A, Pichard AD, Brooks-Robinson S, Rosenberg J, Little T, Lindsay J Jr. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1989;64:294–299.
10. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, Holder D, Finnie K, Marquis JF, Naqvi S, Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR Study. *Circulation* 1996;94:1553–1560.
11. Grigg LE, Kay TW, Valentine PA, Larkins R, Flower DJ, Manolas EG, O'Dea K, Sinclair AJ, Hopper JL, Hunt D. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. *J Am Coll Cardiol* 1989;13:665–672.
12. Kaul U, Sanghvi S, Bahl VK, Dev V, Wasir HS. Fish oil supplements for prevention of restenosis after coronary angioplasty. *Int J Cardiol* 1992;35:87–93.
13. Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. *Circulation* 1992;85:950–956.
14. Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS, Sacks FM, Grossman W, Pasternak RC. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. *Lancet* 1989;2:177–181.
15. Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART [Coronary Angioplasty Restenosis Trial] study. *J Am Coll Cardiol* 1999;33:1619–1626.
16. Maresta A, Balducci M, Varani E, Marzilli M, Galli C, Heiman F, Lavezzari M, Stragliotto E, De Caterina R. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis (Italian Study ESPRIT). *Am Heart J* 2002;143:E5.
17. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. *Lancet* 2003;361:477–485.
18. Rapp JH, Connor WE, Lin DS, Porter JM. Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil: their incorporation into advanced human atherosclerotic plaques. *Arterioscler Thromb* 1991;11:903–911.
19. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1999;130:554–562.
20. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. *J Am Coll Cardiol* 1995;25:1492–1498.
21. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. *Am J Clin Nutr* 1997;65(suppl):1687S–1698S.
22. Olsen SF, Sorensen JD, Secher NJ, Hedegaard M, Henriksen TB, Hansen HS, Grant A. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. *Lancet* 1992;339:1003–1007.
23. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. *J Am Soc Nephrol* 1992;2:1634–1639.
24. Lempert KD, Rogers JS II, Albrink MJ. Effects of dietary fish oil on serum lipids and blood coagulation in peritoneal dialysis patients. *Am J Kidney Dis* 1988;11:170–175.
25. Clarke JT, Cullen-Dean G, Regelink E, Chan L, Rose V. Increased incidence of epistaxis in adolescents with familial hypercholesterolemia treated with fish oil. *J Pediatr* 1990;116:139–141.
26. Goren A, Stankiewicz H, Goldstein R, Drukker A. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. *Pediatrics* 1991;88:265–268.